Read + Share
Burgel PR. Reply to: Supporting the case for a targeted approach for
elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del
CFTR variant: further analysis for the French compassionate use programme. Eur Respir J 2024;63:2400233.
PMID: 38423591
|
 |
|
